S&P 500 Healthcare Sector SEC Filings — March 23, 2026

23-03-2026

AbbVie Inc. released its 2026 Proxy Statement for the Annual Meeting on May 8, 2026, highlighting strong 2025 performance with total net revenues of $61.2B (up 8.5% operationally vs. 2024) driven by Growth Platform revenues of $56.6B (up 19.6% vs. 2024, comprising 93% of total), operating cash flow of $19.0B, and adjusted R&D investment of $13.8B. Key proposals include electing four directors (Jennifer L. Davis, Melody B. Meyer, Robert A. Michael, Frederick H. Waddell), ratifying Ernst & Young LLP as auditor, advisory vote on executive compensation, management proposal to eliminate supermajority voting (recommended FOR), and a stockholder proposal for an independent board chair (recommended AGAINST). Over the past decade, market capitalization increased by $309B, quarterly dividend rose to $1.73 per share, and total stockholder return reached +485%.

• ·Record date: March 9, 2026
• ·Meeting held virtually at www.virtualshareholdermeeting.com/ABBV2026
• ·Nine key assets achieved at least double-digit sales growth in 2025, including Skyrizi (+nearly 50%) and Rinvoq (+40%)
• ·Total stockholder return +485% over the last decade (2015-2025)

23-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 23, 2026, announcing the issuance of a press release regarding the integration of RAD devices into the Immix platform by AITX's RAD and Immix entities. No financial metrics, performance comparisons, or quantitative impacts were disclosed in the filing.

23-03-2026

Heritage Financial Corporation detected a cybersecurity incident on March 2, 2026, involving unauthorized access and exfiltration of files from an internal employee file share server that may contain personal information. While customer accounts, systems, and operations were unaffected with no disruptions to business continuity, the company has launched an investigation with external forensic and legal advisors and notified regulators, law enforcement, and its cyber insurance carrier. As of the March 20, 2026 report date, the incident has not been determined to be material or likely to impact financial condition or results of operations.

• ·Affected system taken offline to contain the incident.
• ·Incident reported under Item 8.01 Other Events in Form 8-K filed March 23, 2026.

23-03-2026

News Corporation filed an 8-K disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing stock repurchase program, under which the company is authorized to acquire up to $1 billion in aggregate of its Class A (NWSA) and Class B (NWS) common stock. The disclosures, attached as Exhibits 99.1 and 99.2, fulfill daily ASX reporting requirements for any transactions under the program. No specific repurchase transactions or amounts were detailed in the filing itself.

• ·Class A Common Stock trades as NWSA on Nasdaq Global Select Market
• ·Class B Common Stock trades as NWS on Nasdaq Global Select Market
• ·Event date: March 20, 2026; Filing date: March 23, 2026

23-03-2026

Aptose Biosciences Inc. filed an 8-K on March 23, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits), announcing the issuance of a press release dated March 23, 2026, attached as Exhibit 99.1 (not deemed 'filed' under Section 18 of the Exchange Act). The filing was signed by William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer. No financial or operational metrics were disclosed in the filing body.

• ·Commission File Number: 001-32001
• ·I.R.S. Employer Identification No.: 98-1136802
• ·Principal Executive Offices: 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, Ontario M5K 1E6, Canada
• ·Telephone: (647) 479-9828

23-03-2026

On March 17, 2026, Jennifer Jarrett notified Arcus Biosciences, Inc. of her resignation as Chief Operating Officer, effective March 30, 2026, stating it was not due to any disagreement with the company's operations, policies, or practices. The company entered into a separation agreement under which Ms. Jarrett will provide periodic advisory services through June 30, 2026, in exchange for an extension of her post-termination vested option exercise period to 12 months.

• ·Separation agreement contains a standard release of claims.
• ·Full separation agreement to be filed with the next Form 10-Q.

23-03-2026

Yunhong Green CTI Ltd reported net sales growth of 10% YoY to $19.7M for the year ended December 31, 2025 from $18.0M in 2024, driven by foil balloons (+11% to $12.8M, 65% of sales) and film products (+33% to $1.1M), while other products grew modestly 4% to $5.8M. However, Customer B sales declined 8% to $7.9M (40% of revenues from 47%), the company recorded a $1.7M impairment on Hubei assets (vs $0 prior year), and depreciation doubled to $641k. Management remains focused on core foil balloon products and leveraging Yunhong Group advancements in compostable materials.

• ·Credit facility entered September 2021, extended in 2025, expires April 2028; in compliance since inception.
• ·55,600 shares under option outstanding and exercisable at Dec 31, 2025, weighted average exercise price $15.20 (unchanged from 2024).
• ·Two customers (A and B) represent 81% of 2025 revenues.

23-03-2026

General Motors Company and General Motors Financial Company, Inc. entered into the Eighth Amended and Restated 364-Day Revolving Credit Agreement dated March 23, 2026, amending and restating the prior Seventh Amended and Restated agreement from March 25, 2025. The facility involves multiple lenders, with JPMorgan Chase Bank, N.A. as Administrative Agent and Citibank, N.A. as Syndication Agent, along with various joint lead arrangers and bookrunners. No specific commitment amounts, pricing grids, or changes in terms are detailed in the filing excerpt.

• ·Filing Type: 8-K, Items: 1.01, 2.03, 9.01
• ·Previous credit agreement effective date: March 25, 2025
• ·Schedules include Commitments (1.1A), Applicable Pricing Grid (1.1C), but details redacted or not provided

23-03-2026

Catheter Precision, Inc. (VTAK) completed Initial and Subsequent Series C Private Placements raising aggregate gross proceeds of $3.47M through issuance of 392,608 common shares and 3,470 Series C-1 Preferred shares convertible into up to 2,426,573 common shares at $1.43 initial conversion price. The proxy seeks stockholder approval for conversion of these and potential additional Series C-2, C-3, and up to $77.8M in C-4 Preferred shares (total potential up to $88.2M), as required under NYSE American rules for issuances exceeding 19.99% of outstanding common stock or voting power. No stockholder approval has been obtained yet, delaying full conversion and additional closings.

• ·Stockholder meeting required within 60 days of February 9, 2026 Initial Closing Date; if not approved, reconvene every 90 days until obtained or preferred shares redeemed.
• ·Series C Preferred conversion prices adjustable to 80% of applicable price (5-day VWAP or closing price) post-Effective Date or Stockholder Approval Date, subject to $0.35 floor (waivable by Company).
• ·Placement agent Dawson James entitled to 7.7% cash fee only on proceeds above $3.85M.
• ·Preferred stockholders have protective veto rights on adverse changes to terms, charter amendments affecting rights, or increasing authorized preferred shares.

23-03-2026

J. Derek Lewis & Associates Inc. filed its 13F-HR on March 23, 2026, disclosing equity holdings as of December 31, 2025, totaling $426.9 million across 209 positions held solely. Top holdings include Capital Group Core Balanced ($40.5M, 1,146,334 shares), Capital Group Dividend Value ($31.4M, 719,370 shares), and Apple Inc. ($18.9M, 69,651 shares), with significant allocations to other Capital Group ETFs/mutual funds, Microsoft ($7.9M), and NVIDIA ($5.2M). No voting or disposition power sharing reported for any positions.

• ·Holdings period end date: December 31, 2025
• ·All positions reported with sole voting and disposition power; no shared power indicated
• ·Heavy concentration in Capital Group ETFs and mutual funds comprising a significant portion of total AUM

23-03-2026

Hewlett Packard Enterprise Company completed an underwritten public offering of $2.0B in senior notes on March 23, 2026, comprising $300M Floating Rate Notes due 2028, $500M 4.500% Notes due 2028, $600M 4.600% Notes due 2029, and $600M 5.250% Notes due 2033. The notes were issued pursuant to a base indenture dated October 9, 2015, supplemented by four new supplemental indentures with The Bank of New York Mellon Trust Company, N.A. as trustee, and registered under Form S-3 (No. 333-276221). No financial performance metrics or period comparisons were disclosed.

• ·Registration statement on Form S-3 (No. 333-276221), effective December 22, 2023.
• ·Base Indenture dated October 9, 2015; Supplemental Indentures: Thirty-Second (Floating Rate Notes), Thirty-Third (2028 Notes), Thirty-Fourth (2029 Notes), Thirty-Fifth (2033 Notes), all dated March 23, 2026.

23-03-2026

On March 19, 2026, the Office of the Comptroller of the Currency approved a deposit acquisition by Axos Bank, a subsidiary of Axos Financial, Inc., as previously disclosed in the company's Form 8-K filed on February 12, 2026. The company expects the transaction to close in the quarter ending June 30, 2026. No financial terms or impacts were disclosed in this filing.

• ·Filing signed and dated March 23, 2026
• ·Securities: Common stock, $0.01 par value (AX) on New York Stock Exchange

23-03-2026

Regions Financial Corporation filed Definitive Additional Materials (DEFA14A) under Schedule 14A on March 23, 2026, as part of its proxy solicitation pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and contains no substantive financial data, metrics, or specific proposals. It serves as supplemental proxy material without detailed content in the provided header.

23-03-2026

First Citizens BancShares, Inc., a top 20 U.S. financial institution with over $200B in assets and more than 18,000 associates, has issued its 2026 proxy statement for the virtual Annual Meeting on May 4, 2026, seeking stockholder approval for electing 12 directors, an advisory vote on executive compensation, ratification of auditors, and a stockholder proposal on faith-based employee resource groups (board recommends against). Voting is based on 10.8M Class A shares (1 vote each) and 1.0M Class B shares (16 votes each) outstanding as of the March 6, 2026 record date. No period-over-period financial performance data is detailed in the filing.

• ·Annual Meeting: May 4, 2026 at 9:00 a.m. EDT, virtual at www.virtualshareholdermeeting.com/FCNCA2026
• ·Record Date: March 6, 2026
• ·Proposals include election of 12 directors (plurality vote), advisory say-on-pay (majority), auditor ratification (majority), stockholder proposal on faith-based ERGs (majority, board opposes)
• ·Company founded in 1898, headquartered in Raleigh, NC

23-03-2026

South Plains Financial, Inc. (SPFI) and BOH Holdings, Inc. (BOH) announced on March 23, 2026, that they have received all required regulatory approvals and non-objections from the Board of Governors of the Federal Reserve System, FDIC, and Texas Department of Banking for their merger under the Reorganization Agreement signed December 1, 2025. BOH shareholders approved the transaction on March 20, 2026. The merger is expected to complete on April 1, 2026, subject to customary closing conditions, with Bank of Houston merging into City Bank thereafter.

• ·SPFI common stock trades on Nasdaq under symbol SPFI.
• ·Regulatory approvals from Board of Governors of the Federal Reserve System, Federal Deposit Insurance Corporation, and Texas Department of Banking.

23-03-2026

Bayview Acquisition Corp received a new Nasdaq delisting notice on March 19, 2026, for failing to comply with Listing Rule 5450(b)(2)(B), requiring at least 1,100,000 publicly held shares, compounding prior deficiencies in market value of listed securities (Rule 5450(b)(2)(A)) and minimum public holders (Rule 5450(a)(2)). The company, facing a delisting determination from February 19, 2026, has a hearing scheduled for March 31, 2026, and submitted a transfer application to Nasdaq Capital Market on December 16, 2025, but success is uncertain with no assurances of regaining compliance.

• ·Nasdaq Listing Rules deficiencies: 5450(b)(2)(A) (market value of listed securities), 5450(a)(2) (minimum public holders), 5450(b)(2)(B) (publicly held shares).
• ·Hearing details: March 31, 2026, at 11:00 a.m. Eastern Time via video conference.
• ·Principal executive offices: 420 Lexington Ave, Suite 2446, New York, NY 10170; Phone: (347) 627-0058.

23-03-2026

On March 19, 2026, the Board of Directors of Newsmax Inc. appointed David Evans as a member to fill an existing vacancy, effective immediately, and also to the Audit Committee alongside Rene Alexander Acosta and Paula J. Dobriansky. The Board determined Mr. Evans to be independent under New York Stock Exchange rules, with compensation per the Director Compensation Policy and no related arrangements or material transactions disclosed. A press release announcing the appointment was issued on March 23, 2026.

• ·Mr. Evans executed the Company’s standard form of indemnification agreement for directors (previously filed as Exhibit 6.7 to Form 1-A on February 7, 2025).
• ·Information in Item 7.01 and Exhibit 99.1 is furnished, not filed, under Regulation FD.

23-03-2026

For the nine months ended January 31, 2026, Sparta Commercial Services reported total revenue of $288,157, up 71% YoY from $168,357, driven by strong growth in merchant financing (+192% to $158,705), while information technology (+15% to $100,496) and wellness products (+10% to $28,956) showed modest gains; however, the company posted a net loss of $1.4M, improved from $1.8M YoY but still reflecting high operating expenses and interest costs. Balance sheet shows total assets at $933K (up 23% from $757K), but cash declined 47% to $70K, liabilities rose to $12.1M, and stockholders' deficit worsened to $11.2M. Operating cash use improved to $725K from $1.2M, funded by $664K in financing activities.

• ·Current portion notes payable increased to $8.99M from $7.97M as of Jan 31, 2026 vs Apr 30, 2025.
• ·Derivative liabilities decreased to $968K from $1.01M.
• ·Weighted average shares outstanding for nine months: 42.88M vs 33.95M prior year.
• ·Net cash provided by financing activities: $664K vs $1.13M prior year.

23-03-2026

The 10-K filing for JPMBB Commercial Mortgage Securities Trust 2014-C18 includes servicing criteria compliance assertions under Regulation AB Item 1122 by servicer Midland and other asserting parties, confirming adherence to most applicable criteria such as policies for monitoring defaults, cash handling, reconciliations, and loss mitigation. Several criteria are marked N/A due to transaction agreement specifics or lack of applicability, with some activities performed by vendors under responsible party oversight. No material deficiencies or exceptions to compliance are reported.

• ·Filing date: March 23, 2026
• ·Multiple servicing criteria marked N/A, including back-up servicer maintenance, investor remittances, and external enhancements
• ·Certain criteria applicable only to 'Platform A' (e.g., Commission filing and record agreement), not 'Platform B'

23-03-2026

Artelo Biosciences, Inc. (ARTL) filed an S-1/A registration statement on March 23, 2026, for a public offering of common stock and pre-funded warrants, with Craft Capital Management LLC as placement agent receiving 8.0% fees and warrants equal to 8.0% of securities sold. Interim Phase 2a CAReS trial results for ART27.13 showed mean body weight gain of 6.38% (n=5 at top dose) versus -5.42% loss in placebo (n=6), with lean body mass +4.23% vs -3.15%, and a favorable safety profile among 32 enrolled patients. Phase 1 SAD study for ART26.12 in 49 healthy subjects reported no drug-related adverse events and linear pharmacokinetics.

• ·ART27.13 daily dose approved up to 1,300 micrograms; CAReS initiated Phase 2a in April 2023 across 18 sites in 5 countries.
• ·ART26.12 IND cleared by FDA in July 2024; Phase 1 results announced June 2025.
• ·ART12.11 composition of matter patent enforceable until December 10, 2038, granted/validated in 21 countries.
• ·Interim CAReS analysis announced September 3, 2025; all AEs mild/moderate except one severe malaise, no serious drug-related AEs.

23-03-2026

Apollo Commercial Real Estate Finance, Inc. (ARI) seeks stockholder approval for the Asset Sale of its commercial real estate loan portfolio (excluding two loans totaling $146M) to Athene for 99.7% of the total commitment amount at closing, expected in Q2 2026, with post-sale net cash of ~$1.4B and retained REO portfolio of $464.3M as of Dec 31, 2025. Proceeds will repay debt and fund a new investment strategy, with a declared $0.25/share Q1 2026 dividend targeting 8% annualized yield on post-closing BVPS; however, failure to approve could trigger a $50M termination fee to Athene and prevent entry into the revised A&R Management Agreement.

• ·Purchase Agreement entered into on January 27, 2026.
• ·Closing requires approval of Asset Sale Proposal, entry into A&R Management Agreement, and deliveries for at least 85% of aggregate purchase price.
• ·No appraisal rights for stockholders; Asset Sale taxable to ARI but not expected to result in taxable income to stockholders.

23-03-2026

The 10-K filing for JPMBB Commercial Mortgage Securities Trust 2015-C27, dated March 23, 2026, provides servicing compliance assertions under Regulation AB Item 1122(d) for servicer Midland and other asserting parties. Most applicable criteria are marked as performed directly by Midland or via responsible vendors, while many others are designated N/A due to inapplicability to their roles; no material noncompliance or exceptions are noted. Investor reporting and loss mitigation criteria are confirmed applicable and compliant where relevant.

23-03-2026

Newbridge Acquisition Ltd, a SPAC, reported total assets increasing to $4.8M as of December 31, 2025 from $95K in 2024, driven by cash rising to $1.8M and $2.7M in trust account. However, related-party promissory notes surged to $5.4M from $0.5M, and accumulated deficit grew to $620K from $399K, deepening shareholders' deficit to $595K. Class B ordinary shares outstanding halved to 1.44M.

• ·Deferred offering costs increased to $295K from $85K as of Dec 31 2025 vs 2024.
• ·Audited by Independent Registered Public Accounting Firm (PCAOB ID 6907).

23-03-2026

Ensysce Biosciences, Inc. filed a Certificate of Correction to its Certificate of Designation of Series B Preferred Stock, correcting a scrivener’s error in Section 4(d)(ii) concerning Principal Market Regulation and the Exchange Cap limits on Common Stock issuances upon conversion. The amended section clarifies restrictions under NASDAQ Listing Rule 5635(d), including pro rata allocations for holders and exceptions for stockholder approval or legal opinions. The correction was executed on March 12, 2026, by CEO Dr. Lynn Kirkpatrick, for the original filing dated November 14, 2025.

• ·Original Certificate of Designation filed with Delaware Secretary of State on November 14, 2025.
• ·8-K filing date: March 23, 2026, covering Items 5.03 and 9.01.

23-03-2026

Stryker Corporation updated on its cybersecurity incident disclosed in prior 8-K filings on March 11 and 12, 2026, confirming the incident is contained with no evidence of threat actor access to customer, supplier, vendor, or partner systems, no ransomware, and a malicious file that did not spread. Assisted by Palo Alto Networks Unit 42, the company issued a General Assurance letter (Exhibit 99.1) and website statement (Exhibit 99.2) reflecting network disruptions including Microsoft environment. However, the investigation is ongoing, with scope, nature, operational, and potential financial impacts still being assessed, and materiality undetermined.

• ·Previous disclosures via 8-K on March 11, 2026, and March 12, 2026.
• ·Updates communicated via Stryker.com website and social media.
• ·Information under Item 7.01 not deemed 'filed' under Section 18 of Exchange Act.

23-03-2026

Core Scientific, Inc. (Nasdaq: CORZ) closed an additional $500 million commitment from JPMorgan Chase Bank, N.A., expanding its 364-day credit facility to a total of $1.0 billion, including a prior $500 million from Morgan Stanley. Borrowings under the facility bear interest at SOFR plus 2.50% and will be used for general corporate purposes, including data center asset development to meet strong demand. CEO Adam Sullivan stated the company is well-positioned to execute its strategy.

• ·The credit facility is a 364-day term.
• ·Proceeds to be used for equipment purchases, pre-development costs, real property acquisitions, and additional energy procurement for data centers.
• ·Company operates facilities for high-density colocation and is converting to support AI-related workloads.

23-03-2026

Gladstone Commercial Corporation (Nasdaq: GOOD) announced a strategic succession plan effective immediately on March 23, 2026, with founder David Gladstone stepping down as CEO to remain Chairman of the Board and involved in key roles, while Arthur 'Buzz' Cooper was appointed CEO and President. Additional promotions include John Sateri as Chief Investment Officer, Gary Gerson as Executive Vice President (in addition to CFO and Assistant Treasurer), and Ryan Carter as Executive Vice President. The changes emphasize management depth and separate Chairman/CEO roles for better governance, highlighting the REIT's growth to over 150 single-tenant net leased industrial properties as of December 31, 2025.

• ·David Gladstone founded the company in 2003 and led it from IPO to current status.
• ·Company's 10-K for fiscal year ended December 31, 2025, filed with SEC on February 18, 2026.
• ·Gladstone family of funds celebrating 25th year in business.

23-03-2026

Cingulate Inc. filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration statement (Reg. No. 333-292680, originally filed January 12, 2026) solely to include an updated consent from independent auditor KPMG LLP (Exhibit 23.1); no changes were made to the prospectus. The registration covers various securities (common stock, preferred stock, warrants, debt securities, units) for potential sales by a selling stockholder on a delayed or continuous basis under Rule 415 after effectiveness. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

• ·Incorporated in Delaware; SIC code 2834; I.R.S. Employer Identification Number 86-3825535.
• ·Principal executive offices: 1901 W. 47th Place, Kansas City, KS 66205; phone (913) 942-2300.
• ·Original Registration Statement filed January 12, 2026.

23-03-2026

Roivant Sciences Ltd. filed an 8-K/A amendment on March 23, 2026, to include the Settlement Agreement dated March 3, 2026, between its subsidiary Genevant Sciences GmbH, Arbutus Biopharma Corp., Genevant Sciences Ltd., and Moderna, Inc./ModernaTx, Inc. This agreement resolves all pending U.S. and international patent infringement litigations related to Moderna's use of Genevant/Arbutus' lipid nanoparticle delivery technology in vaccines. No financial terms or other quantitative details are disclosed in the filing.

23-03-2026

Bally's Corporation (BALY) reported total revenue of $2.44B for the Successor period (February 8 to December 31, 2025), nearly flat compared to the full-year 2024 revenue of $2.45B (-0.6%), while combined 2025 revenue reached $2.66B, up 8.5% YoY; gaming revenue declined to $1.99B in Successor from $2.05B prior year, but non-gaming rose to $447M from $399M. Net loss widened significantly to $666M in Successor (combined 2025 $717M vs. $568M in 2024), driven by $182M impairments, higher interest expense ($365M), and transaction costs. Adjusted EBITDA dipped slightly to $478M from $496M prior year, though total assets expanded to $11.2B amid acquisition-related growth in goodwill and intangibles.

• ·Operating cash flow negative at $(11M) for Successor period vs. $114M positive in 2024.
• ·Net cash from investing $1.84B Successor, driven by transaction proceeds.
• ·Total liabilities $8.69B at Dec 31, 2025 vs. $5.83B at Dec 31, 2024.
• ·Goodwill increased to $3.43B from $1.80B.
• ·Rent expense on triple net leases $159M Successor vs. $119M prior year.

23-03-2026

Baxter International Inc. (BAX) filed Definitive Additional Proxy Materials (DEFA14A) on March 23, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. This filing includes no substantive financial data, performance metrics, or period-over-period comparisons. It serves as additional soliciting material for shareholders with no fee required.

• ·Filing Type: DEFA14A (Definitive Additional Materials)
• ·Filed by the Registrant
• ·No fee required for filing

23-03-2026

Abbott Laboratories completed its acquisition of Exact Sciences Corporation on March 23, 2026, via a merger with Badger Merger Sub I, Inc., pursuant to the Merger Agreement dated November 19, 2025. Each share of Exact Sciences common stock was converted into $105.00 in cash. No financial performance metrics or period-over-period comparisons were disclosed in the filing.

• ·Filing includes Exhibit 2.1 (Merger Agreement, incorporated by reference from November 20, 2025 8-K) and Exhibit 99.1 (Press Release dated March 23, 2026).

23-03-2026

Exact Sciences Corporation filed its Seventh Amended and Restated Certificate of Incorporation as Exhibit 3.1 to an 8-K, reducing authorized common stock to 1,000 shares with $0.01 par value. The amendment includes standard provisions limiting director liability for breaches of fiduciary duty (with exceptions) and extensive indemnification protections for directors and officers against legal expenses in civil, criminal, and derivative actions. This governance update accompanies 8-K items indicating completion of an acquisition, entry/termination of material agreements, changes in control, director/officer departures, and material modifications to security holder rights.

• ·Registered office: Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801.
• ·Indemnification decisions to be made by disinterested directors, independent counsel, stockholder vote, or court within 60 days of request.

23-03-2026

PROCACCIANTI HOTEL REIT, INC. reported total NAV of $59.2M as of December 31, 2025, with rooms revenues increasing 1.50% YoY to $28.6M, driven by growth at Hilton Garden Inn Providence (+12.12%) and Hotel Indigo Traverse City (+4.23%); however, declines at Staybridge Suites St. Petersburg (-7.39%), Springhill Suites Wilmington (-4.37%), and flat performance at Cherry Tree Inn (-0.27%) contributed to a YoY drop in net income to $1.9M from $2.1M and essentially flat total distributions at $3.8M. MFFO attributable to common stockholders was slightly down to $5.2M from $5.3M YoY, while average annual occupancy was 70.80% with RevPAR of $139.94.

• ·Share repurchase program limited to 5.0% of weighted average K, K-I, and K-T shares outstanding over trailing 12 months.
• ·Estimated Per Share NAV: Class K/K-I $10.17, Class A $7.14, Class B $0.00.
• ·2025 Q4 average occupancy 58.57% (lowest quarterly), RevPAR $99.41.
• ·FFO attributable to common stockholders $5.0M in 2025 vs $5.2M in 2024.

23-03-2026

Greenland Mines Ltd (Nasdaq: GRLM) received a six-month extension from Nasdaq until September 14, 2026, to regain compliance with the minimum $1.00 bid price rule after missing the initial March 18, 2026 deadline from a September 19, 2025 non-compliance notice. The extension acknowledges compliance with all other Nasdaq listing standards, but failure to achieve a $1.00 closing bid price for 10 consecutive business days risks delisting. The company highlighted its Skaergaard Project resources of 25.4 Moz PdEq and 23.5 Moz AuEq valued at approximately $68B in-situ.

• ·Company holds 80% interest in Skaergaard Project with option to acquire remaining 20%.
• ·Mineral Resources per 2022 NI 43-101 technical report; not Mineral Reserves and no demonstrated economic viability.